Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2984951 | 0.89 | TDP1 (0.60) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL19840200 | 0.88 | TDP1 (0.55) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL1728757 | 0.84 | ALDH1A1 (0.66) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL6693656 | 0.83 | KMT2A (0.64) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| Dimethyl Phthalate SCHEMBL7826081 | 0.83 | KMT2A (0.69) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL2987926 | 0.82 | TDP1 (0.51) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL20831011 | 0.82 | TDP1 (0.58) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL27806908 | 0.82 | RAB9A (0.52) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL1730827 | 0.82 | ALDH1A1 (0.59) | KMT2ATDP1SLC6A2SLC6A3LMNA | |
| SCHEMBL7015523 | 0.81 | ALDH1A1 (0.55) | KMT2ATDP1SLC6A2SLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636192-B9 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL IND LTD (JP) | 2015-07-01 | — | — | EP | disclosed |
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2014-02-20 | — | — | US | disclosed |
| EP-1636192-B1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL IND LTD (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
| US-8318796-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20110077290-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20100173896-A1 | Organic Compounds | SAKAKI JUNICHI | 2010-07-08 | — | — | US | disclosed |
| US-20100173896-A1 | Organic Compounds | SAKAKI JUNICHI | 2010-07-08 | — | — | US | disclosed |
| US-20100173896-A1 | Organic Compounds | SAKAKI JUNICHI | 2010-07-08 | — | — | US | disclosed |
| US-7709470-B2 | 11-phenyl-dibenzodiazepine derivatives as RXR-antagonists | NOVARTIS AG (CH) | 2010-05-04 | — | — | US | disclosed |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20070043029-A1 | 11-Phenyl-dibenzodiazepine derivatives as rxr-antagonists | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
| US-20070043029-A1 | 11-Phenyl-dibenzodiazepine derivatives as rxr-antagonists | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
| US-20070043029-A1 | 11-Phenyl-dibenzodiazepine derivatives as rxr-antagonists | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
| CN-1798739-A | 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD (JP) | 2006-07-05 | — | — | CN | disclosed |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1636192-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
| EP-1618096-A1 | 11-PHENYL-DIBENZODIAZEPINE DERIVATIVES AS RXR-ANTAGONISTS | Novartis AG (CH) | 2006-01-25 | — | — | EP | disclosed |
| WO-2004108683-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004089916-A1 | 11-PHENYL-DIBENZODIAZEPINE DERIVATIVES AS RXR-ANTAGONISTS | NOVARTIS AG (CH) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077290-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | KMT2A 3762/4885TDP1 4730/4885SLC6A2 3144/4885 |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NR2C2, ROR1, NR0B2 | KMT2A 3696/4885TDP1 4740/4885SLC6A2 3243/4885 |
| US-20070043029-A1 | 11-Phenyl-dibenzodiazepine derivatives as rxr-antagonists | RXRB, RXRA, RXRG | KMT2A 1908/4885TDP1 2598/4885SLC6A2 3553/4885 |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | KMT2A 3797/4885TDP1 4716/4885SLC6A2 3059/4885 |
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | KMT2A 3762/4885TDP1 4730/4885SLC6A2 3144/4885 |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | KMT2A 3762/4885TDP1 4730/4885SLC6A2 3144/4885 |
| US-20100173896-A1 | Organic Compounds | RXRB, RXRA, RXRG | KMT2A 908/4885TDP1 3317/4885SLC6A2 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.